TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Evommune and Accutar Biotechnology Unveil Collaboration in AI-Driven Drug Discovery

Wednesday, November 29, 2023

Evommune, Inc., a biotechnology company dedicated to exploring and advancing new methods for treating immune-mediated inflammatory diseases, has joined forces with Accutar Biotechnology Inc., a company specializing in AI-aided drug discovery. This partnership focuses on the exploration of novel small molecule drug candidates for chronic inflammatory diseases. The collaboration intends to make use of Accutar's proprietary AI platform and Evommune's expertise in designing and developing novel oral small molecule treatments that target the root causes of chronic immune-mediated inflammatory diseases. The terms of the agreement have not been disclosed.

Evommune, expressed excitement about the collaboration, stating, "We are thrilled to collaborate with Accutar, a leader in expediting drug discovery, to identify and validate novel targets that could have a profound impact on chronic inflammatory diseases." Dr. Patel highlighted Accutar's sophisticated hybrid approach, combining computational drug design with wet lab validation, to overcome the limitations of traditional drug discovery methods. The objective is to efficiently design safe and effective therapies for complex chronic inflammatory diseases. Dr. Patel mentioned their previous collaboration with Accutar on a program targeting PKCθ and expressed enthusiasm about expanding this partnership in a broader capacity.

Jie Fan, Ph.D., Chief Executive Officer of Accutar, underscored the significant threat posed by chronic inflammatory diseases to human health, with nearly 60 percent of individuals in the U.S. alone experiencing at least one chronic condition. Dr. Fan is eager about partnering with Evommune, citing the company's profound understanding of inflammatory diseases and extensive expertise in clinical development. The collaboration aims to integrate Evommune's biological insights with Accutar's AI-empowered medicinal chemistry engine, with the confidence that this collaboration will lead to the development of the next generation of therapies for chronic inflammatory diseases.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit